glp-1 r retatrutide Retatrutide, a GIP, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Day 8 on Retatrutide. Figured

10.1126/science.1081447 138 TeraoI.KodamaW

What makes the triple agonist approach so compelling is how it leverages glucagon to increase energy expenditure alongside the appetite suppressing effects of GLP-1 and GIP

Ferns, Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Patients with complex medical histories, unexplained symptoms, pregnancy considerations, immune disorders, active cancer concerns, severe allergies, medication interactions, or competitive sport obligations should avoid self-directed use and seek medical guidance

Results from the pilot informed the final survey design, which was implemented across 15 countries, targeting 4,500 adults per country

Clinicians are faced with untangling many differences in trial design and patient characteristics, and an absence of any direct head-to-head insights